Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 17 of 198 for:    Open Studies | "Rectal Neoplasms"

Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Washington University School of Medicine
Information provided by (Responsible Party):
Washington University School of Medicine Identifier:
First received: April 9, 2014
Last updated: November 10, 2014
Last verified: November 2014

This pilot clinical trial studies gene expression analysis and fludeoxyglucose F 18 (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in evaluating treatment response in patients with rectal cancer that has spread to nearby tissue or lymph nodes undergoing chemotherapy and radiation therapy before surgery. Studying samples of tissue in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and may also help doctors predict a patient's response to treatment before surgery. PET-MRI is a procedure that combines the pictures from a PET scan and an MRI scan. The combined scans give more detailed pictures of areas inside the body than either scan gives by itself. PET-MRI may help determine how well people respond to pre-surgery chemotherapy and radiation therapy and help the surgeon make the best plan for removal of the tumor.

Condition Intervention
Rectal Neoplasms
Radiation: fludeoxyglucose F 18
Device: positron emission tomography
Device: magnetic resonance imaging
Other: laboratory biomarker analysis

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Pilot Study of Gene Expression and FDG-PET/MR Biomarkers for Evaluation of Response to Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Resource links provided by NLM:

Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Change in FDG-PET/MR SUVmax [ Time Frame: Baseline to up to 2 weeks before surgery ] [ Designated as safety issue: No ]
    Images will be evaluated semi-quantitatively. Changes in imaging parameters will be correlated with pathologic response.

  • Change in FDG-PET/MR SUVmean [ Time Frame: Baseline to up to 2 weeks before surgery ] [ Designated as safety issue: No ]
    Images will be evaluated semi-quantitatively. Changes in imaging parameters will be correlated with pathologic response.

  • Change in ADCmean [ Time Frame: Baseline to up to 2 weeks before surgery ] [ Designated as safety issue: No ]
    Images will be evaluated semi-quantitatively. Changes in imaging parameters will be correlated with pathologic response.

  • Radiosensitivity index [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Index is calculated based on tumor gene expression. Will be correlated with the descriptive changes in FDG-PET/MR SUV and ADC parameters.

Estimated Enrollment: 25
Study Start Date: June 2014
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Diagnostic (FDG PET/MRI, gene expression)
FDG PET/MRI at baseline and at 2-4 weeks before surgery (after neoadjuvant chemoradiation). Tissue samples for gene expression at baseline and during surgery
Radiation: fludeoxyglucose F 18
Other Name: 18 FDG, 18FDG, 2-F18-fluoro-2-deoxy-D-glucose, 2-F18-fluoro-2-deoxyglucose, 63503-12-8, FDG, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18
Device: positron emission tomography
Other Name: FDG-PET, PET, PET scan, tomography, emission computed
Device: magnetic resonance imaging
Other Name: MRI, NMR imaging, NMRI, nuclear magnetic resonance imaging
Other: laboratory biomarker analysis
Correlative studies


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy-proven adenocarcinoma of the rectum.
  • Surgical candidate.
  • Candidate for neoadjuvant chemotherapy.
  • Clinical evidence of T1-3N1 or T3N0 disease. This can be either by imaging studies or by physical exam findings.
  • At least 18 years of age.
  • Zubrod performance status of 0-2.
  • Able to understand and willing to sign a written informed consent document.
  • Patients with distant metastatic disease will be eligible if they satisfy all other conditions.

Exclusion Criteria:

  • Pregnant.
  • Past history of pelvic radiotherapy.
  • Received prior chemotherapy for colorectal cancer.
  • Uncontrolled diabetes with a fasting glucose ≥ 200 mg/dl at the time of PET/MRI imaging.
  • Claustrophobia or any other contraindication to MRI imaging evaluated by a standardized safety questionnaire.
  • Renal insufficiency (defined as glomerular filtration rate (GFR < 30 mL/min/1.73 m2) measured no more than 60 days before the first research scan) which precludes safe administration of the contrast agent.
  • Currently on dialysis.
  • Known prior allergic reaction to gadolinium-based MR contrast agents.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02112162

Contact: Jeffrey Olsen, M.D. 314-330-3539

United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Jeffrey Olsen, M.D.    314-330-3539   
Sub-Investigator: Hussam Al-Kateb, M.Sc., Ph.D.         
Sub-Investigator: Manik Amin, M.D.         
Sub-Investigator: Elisa Birnbaum, M.D.         
Sub-Investigator: Danielle Carpenter, M.D.         
Sub-Investigator: Farrokh Dehdashti, M.D.         
Sub-Investigator: Todd DeWees, Ph.D.         
Sub-Investigator: Sekhar Dharmarajan, M.D.         
Sub-Investigator: Kathryn Fowler, M.D.         
Sub-Investigator: Yanle Hu, Ph.D.         
Sub-Investigator: Steven Hunt, M.D.         
Sub-Investigator: A. Craig Lockhart, M.D.         
Sub-Investigator: Matthew Mutch, M.D.         
Sub-Investigator: Vamsi Narra, M.D.         
Sub-Investigator: Parag Parikh, M.D.         
Sub-Investigator: Joel Picus, M.D.         
Sub-Investigator: Caron Rigden, M.D.         
Sub-Investigator: Matthew Silviera, M.D.         
Sub-Investigator: Steven Sorscher, M.D.         
Sub-Investigator: Rama Suresh, M.D.         
Sub-Investigator: Benjamin Tan, M.D.         
Sub-Investigator: Andrea Wang-Gillam, M.D., Ph.D.         
Sub-Investigator: Paul Wise, M.D.         
Sponsors and Collaborators
Washington University School of Medicine
Principal Investigator: Jeffrey Olsen, M.D. Washington University School of Medicine
  More Information

Additional Information:
No publications provided

Responsible Party: Washington University School of Medicine Identifier: NCT02112162     History of Changes
Other Study ID Numbers: 201401064
Study First Received: April 9, 2014
Last Updated: November 10, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Rectal Neoplasms
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Fluorodeoxyglucose F18
Anti-Infective Agents
Antiviral Agents
Diagnostic Uses of Chemicals
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 27, 2014